Vyzhivaemost' bol'nykh terminal'noy khronicheskoy pochechnoy nedostatochnost'yu, poluchayushchikh postoyannyy ambulatornyy peritoneal'nyy dializ


Cite item

Full Text

Abstract

Aim. Estimation of cumulative survival and factors of unfavorable prognosis in patients with terminal renal failure, receiving continuous peritoneal dialysis (CAPD).
Methods. In 20 male and 30 female on CAPD were performed echocardiocardiography (in dry and full with dialysis solution abdominal cavity), 24-hour ECG-monitoring and blood pressure monitoring, ultrasound scanning of kidneys and vena cava inferior.
Results. Cardiovascular complications were major (33,4% among all causes) cause of death in patients on CAPD. The leadings factors of cardiovascular remodeling in CAPD patients were serum albumin level <38 g/l, latent or evident hyperhydratation, low residual kidney function and levels of fractional urea clearance and creatinine clearance below the goal values.
Conclusion. Cardiovascular causes are the leading cause of death in CAPD patients.

References

  1. Hoeben H., Van Biesen W., Lameire N. Cardiovascular problems in peritoneal dialysis: a short overview. Peritoneal Dialysis International 1999; 19 (Suppl. 2): 1345-1356
  2. Ahmet T., Mehmet K., Hakan T. et al. Inferior vena cava diameter determines left ventricular geometry in continuous ambulatory peritoneal dialysis patients: an echocardiographic study. Nephrol Dial Transplant 2003; 18: 2128-2133.
  3. Dejardin A., Robert A., Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications. Nephrol. Dial. Transplant. 2007 22(5):1437-1444
  4. Prichard S.S. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14: S315-S320
  5. Ivarsen P., Povlsen J.V., Jensen J.D. Increasing fill volume reduces cardiac performance in peritoneal dialysis. Nephrol. Dial. Transplant. 2007; 22(10):2999-3004
  6. Graham W. Methodology of assesment of fluid status and ultrafiltration problems. Perit Dial Int, 2007, 27(Supplement 2): 143-147
  7. Chung S.H <http://www.ncbi.nlm.nih.gov./pubmed?term=%22Chung%20SH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Heimbьrger O <http://www.ncbi.nlm.nih.gov./pubmed?term=%22Heimb%C3%BCrger%20O%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Stenvinkel P <http://www.ncbi.nlm.nih.gov./pubmed?term=%22Stenvinkel%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>. et al. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant. <javascript:AL_get(this,%20'jour',%20'Nephrol%20Dial%20Transplant.');> 2003 Mar; 18(3): 590-597
  8. Vonesh E <http://www.ncbi.nlm.nih.gov./pubmed?term=%22Vonesh%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>. On small solute clearance and patient outcomes: evidential practice or observational trepidation? Perit. Dial. Int. <javascript:AL_get(this,%20'jour',%20'Perit%20Dial%20Int.');> 2009; 29(6): 623-629
  9. Enia G. <>, Mallamaci F., Benedetto F.A. et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
  10. Kocnaj D <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ko%C3%A7inaj%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Gashi M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gashi%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Berisha M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Berisha%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. et al. Echocardiographic assessment of left atrial size in patients with end-stage renal disease. Cardiovasc. J. Afr. 2009; 20(3): 183-186
  11. Zoccali C., Benedetto F.A., Tripepi G. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int. 1998; 53: 1078-1084
  12. Weiss G., Lhotta K., Reibnegger G. et al. Divergent effects of hemodialysis and continuous ambulatory peritoneal dialysis on cardiac diastolic function. Perit. Dial. Int. <javascript:AL_get(this,%20'jour',%20'Perit%20Dial%20Int.');> 1997; 17(4): 353-359
  13. Foley R.N., Parfrey P.S. Cardiovascular disease and mortality in ESRD. J. Nephrol. 1998; 11 (5): 239-245.
  14. Ветчинникова О.Н., Агальцов М.В., Пронина В.П. и др. Характер суточного ритма артериального давления у больных с хронической почечной недостаточностью, находящихся на перитонеальном диализе. Тер. арх. 2009; 81(8): 57-61
  15. Vanholder R., Argiles A., Baurmeisteru P. et al. Uremic toxicity: present state of the art. Int. J. Artif. Org. 2001; 24(10): 695 - 725
  16. Vanholder R., Glorieux G., Lameire N. for the European Uremic Toxin Work Group (EUTox). Uraemic toxins and cardiovascular disease. Nephrol. Dial. Transplant. 2003; 18: 463 - 466
  17. Jager K.J., Merkus M.P., Dekker F.W. et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int. 1999; 55(4): 1476-1485
  18. Даугирдас Д.Т., Блейк П.Дж., Тодд С.И. Центр диализа. В: Денисов А.Ю., Шило В.Ю. (ред. перевода с английского) Руководство по диализу. М., 2003: 528-547
  19. Mall G., Rambausek M., Neumeister A et al. Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int. 1988; 33(4): 804-811
  20. Neumann J., Ligtenberg G., Klein I. et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; (49): 506-510
  21. Suzuki H., Kanno Y., Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am. J. Kidney Dis 2004; 43: 1056 -1064
  22. Wang A.Y., Wang M., Wo J., Lam C. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J. Am. Soc. Nephrol. 2003; 14: 159-168
  23. Trespalacios F.C., Taylor A.J., Agodoa L.Y. et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am. J. Kidney Dis. 2003; 41(6): 1267-1277
  24. Ganesh S.K., Hulbert-Shearon T., Port F.K. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J. Am. Soc. Nephrol. 2003; 14: 415-424
  25. Томилина Н.А. Перитонеальный диализ в лечении хронической почечной недостаточности: достоинства, эффективность, проблемы длительного применения. Нефрология и диализ 2000; 2 (1 - 2): 2 - 16

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies